Anaplastic Lymphoma Kinase: Role in specific tumours, and development of small molecule inhibitors for cancer therapy

Cancer Letters

Volumn 299, Issue 2, 2010, Pages 81-94

  Ardini, E ^a   Magnaghi, P ^a   Orsini, P ^a   Galvani, A ^a   Menichincheri, M ^a  

^a NERVIANO MEDICAL SCIENCES   (Italy)

Author keywords

ALCL; ALK; Kinase inhibitor; Neuroblastoma; NSCLC; PF 2341066

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; ANTINEOPLASTIC AGENT; AP 26113; CEP 14513; CYCLOPHOSPHAMIDE; DOXORUBICIN; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; GSK 1838705A; HYBRID PROTEIN; NUCLEOPHOSMIN; NVP TAE 684; ONCOPROTEIN; PREDNISONE; PROTEIN CLTC; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN; TETRAHYDROPYRIDOPYRAZINE DERIVATIVE; TROPOMYOSIN; UNCLASSIFIED DRUG; VINCRISTINE;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ASIAN; AUTOPHOSPHORYLATION; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; DRUG MECHANISM; DRUG RESISTANCE; DRUG SELECTIVITY; DRUG TARGETING; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE STRUCTURE; GERMLINE MUTATION; GLIOBLASTOMA; HUMAN; HYPERTRANSAMINASEMIA; LARGE CELL LYMPHOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; NEUROBLASTOMA; NONHUMAN; ONCOGENE; PLASMA CELL GRANULOMA; POPULATION GENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPEATED DRUG DOSE; RHABDOMYOSARCOMA; SHORT SURVEY; SOMATIC MUTATION; TISSUE DISTRIBUTION; TUMOR CELL; VISUAL IMPAIRMENT;

EID: 78049353081     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.09.001     Document Type: Review

References (126)

1. Li R., Morris S.W. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med. Res. Rev. 2008, 28:372-412.
2. Chiarle R., Voena C., Ambrogio C., Piva R., Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat. Rev. Cancer 2008, 8:11-23.
3. Webb T.R., Slavish J., George R.E., Look A.T., Xue L., Jiang Q., Cui X., Rentrop W.B., Morris S.W. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev. Anticancer Ther. 2009, 9:331-356.
4. Mossé Y.P., Wood A., Maris J.M. Inhibition of ALK signalling for cancer therapy. Clin. Cancer Res. 2009, 15:5609-5614.
5. Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G., Shapiro D.N., Saltman D.L., Look A.T. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994, 263:1281-1284.
6. Shiota M., Fujimoto J., Semba T., Satoh H., Yamamoto T., Mori S. Hyperphosphorylation of a novel 80kDa protein tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 1994, 9:1567-1574.
7. Iwahara T., Fujimoto J., Wen D., Cupples R., Bucay N., Arakawa T., Mori S., Ratzkin B., Yamamoto T. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997, 14:439-449.
8. Morris S.W., Naeve C., Mathew P., James P.L., Kirstein M.N., Cui X., Witte D.P. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997, 14:2175-2188.
9. Donella-Deana A., Marin O., Cesaro L., Gunby R.H., Ferrarese A., Coluccia A.M.L., Tartari C.J., Mologni L., Scapozza L., Gambacorti-Passerini C., Pinna L.A. Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity. Biochemistry 2005, 44:8533-8542.
10. Duyster J.M., Bai R.-Y., Morris S.W. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 2001, 20:5623-5637.
11. Stoica G.E., Kuo A., Aigner A., Sunitha I., Souttou B., Malerczyk C., Caughey D.J., Wen D., Karavanov A., Riegel A.T., Wellstein A. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J. Biol. Chem. 2001, 276:16772-16779.
12. Stoica G.E., Kuo A., Powers C., Bowden E.T., Buchert-Sale E., Riegel A.T., Wellstein A. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J. Biol. Chem. 2002, 277:35990-35999.
13. Lu K.V., Jong K.A., Kim G.Y., Singh J., Dia E.Q., Yoshimoto K., Wang M.Y., Cloughesy T.F., Nelson S.R., Mischel P.S. Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J. Biol. Chem. 2005, 280:26953-26964.
14. Pulford K., Lamant L., Morris S.W., Butler L.H., Wood K.M., Stroud D., Delsol G., Mason D.Y. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997, 89:1394-1404.
15. Vernersson E., Khoo N.K.S., Henriksson M.L., Roos G., Palmer R.H., Hallberg B. Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Exp. Patterns 2006, 6:448-461.
16. Yanagisawa H., Komuta Y., Kawano H., Toyoda M., Sango K. Pleiotrophin induces neurite outgrowth and up-regulates growth-associated protein (GAP)-43 mRNA through the ALK/GSK3beta/beta-catenin signaling in developing mouse neurons. Neurosci. Res. 2010, 66:111-116.
17. Mi R., Chen W., Höke A. Pleiotrophin is a neurotrophic factor for spinal motor neurons. Proc. Natl. Acad. Sci. USA 2007, 104:4664-4669.
18. Bilsland J.G., Wheeldon A., Mead A., Znamenskiy P., Almond S., Waters K.A., Thakur M., Beaumont V., Bonnert T.P., Heavens R., Whiting P., McAllister G., Munoz-Sanjuan I. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology 2008, 33:685-700.
19. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weisstaub N., Lee J., Duman R., Arancio O., Belzung C., Hen R. Requirement of hippocampal neurogenesis for the behavioural effects of antidepressants. Science 2003, 301:805-809.
20. Bruel-Jungerman E., Laroche S., Rampon C. New neurons in the dentate gyrus are involved in the expression of enhanced long-term memory following environmental enrichment. Eur. J. Neurosci. 2005, 21:513-521.
21. Cessna M.H., Zhou H., Sanger W.G., Perkins S.L., Tripp S., Pickering D., Daines C., Coffin C.M. Expression of ALK1 and p80 in inflammatory myofibroblastic tumour and its mesenchymal mimics: a study of 135 cases. Mod. Pathol. 2002, 15:931-938.
22. Pillay K., Govender D., Chetty R. ALK protein expression in rhabdomyosarcomas. Histopathology 2002, 41:461-467.
23. Li X.-Q., Hisaoka M., Shi D.-R., Zhu X.-Z., Hashimoto H. Expression of anaplastic lymphoma kinase in soft tissue tumours: an immunohistochemical and molecular study of 249 cases. Human Pathol. 2004, 35:711-721.
24. Dirks W.G., Fähnrich S., Lis Y., Becker E., MacLeod R.A.F., Drexler H.G. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumour cell lines. Int. J. Cancer 2002, 100:49-56.
25. Cao L., Yu Y., Bilke S., Walker R.L., Mayeenuddin L.H., Azorsa D.O., Yang F., Pineda M., Helman L.J., Meltzer P.S. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res. 2010, 70:6497-6508.
26. Powers C., Aigner A., Stoica G.E., McDonnell K., Wellstein A. Pleiotrophion signalling through anaplstic lymphoma kinase is rate-limiting for glioblastoma growth. J. Biol. Chem. 2002, 277:14153-14158.
27. Grzelinsky M., Steinberg F., Martens T., Czubayko F., Lamszus K., Aigner A. Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia 2009, 11:145-156.
28. Grzelinski M., Bader N., Czubayko F., Aigner A. Ribozyme-targeting reveals the rate-limiting role of pleiotrophin in glioblastoma. Int. J. Cancer 2005, 117:942-951.
29. Maris J.M., Hogarty M.D., Bagatell R., Cohn S.L. Neuroblastoma. Lancet 2007, 369:2106-2120.
30. Lamant L., Pulford K., Bischof D., Morris S.W., Mason D.Y., Delsol G., Mariame B. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am. J. Pathol. 2000, 156:1711-1721.
31. Mossé Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P., Laureys G., Speleman F., Kim C., Hou C., Hakonarson H., Torkamani A., Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M., Maris J.M. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455:930-935.
32. Janoueix-Lerosey I., Lequin D., Brugières L., Ribeiro A., de Pontual L., Combaret V., Raynal V., Puisieux A., Schleiermacher G., Pierron G., Valteau-Couanet D., Frebourg T., Michon J., Lyonnet S., Amiel J., Delattre O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008, 455:967-970.
33. Chen Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M., Wang L., Soda M., Kikuchi A., Igarashi T., Nakagawara A., Hayashi Y., Mano H., Ogawa S. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 455:971-974.
34. George R.E., Sanda T., Hanna M., Fröhling S., Luther W., Zhang J., Ahn Y., Zhou W., London W.B., McGrady P., Xue L., Zozulya S., Gregor V.E., Webb T.R., Gray N.S., Gilliland D.G., Diller L., Greulich H., Morris S.W., Meyerson M., Look A.T. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008, 455:975-978.
35. Wood A.C., Laudenslager M., Haglund E.A., Attiyeh E.F., Pawel B., Courtright J., Plegaria J., Christensen J.G., Maris J.M., Mossé Y.P. Inhibition of ALK mutated neuroblastomas by the selective inhibitor PF-02341066. J. Clin. Oncol. 2009, 27(15S).
36. Passoni L., Longo L., Collini P., Coluccia A.M.L., Bozzi F., Podda M., Gregorio A., Gambini C., Garaventa A., Pistoia V., Del Grosso F., Tonini G.P., Cheng M., Gambacorti-Passerini C., Anichini A., Fossati-Bellani F., Di Nicola M., Luksch R. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res. 2009, 69:7338-7346.
37. Rosenwald A., Ott G., Pulford K., Katzenberger T., Kuhl J., Kalla J., Ott M.M., Mason D.Y., Muller-Hermelink H.K. T(1;2)(q21;p23) and t(2;3)(p23;q21): Two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma. Blood 1999, 94:362-364.
38. Ma Z., Cools J., Marynen P., Cui X., Siebert R., Gesk S., Schlegelberger B., Peeters B., De Wolf-Peeters C., Wlodarska I., Morris S.W. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 2000, 95:2144-2149.
39. Ma Z., Hill D.A., Collins M.H., Morris S.W., Sumagi J., Zhon M., Zuppan C., Bridge J.A. Fusion of ALK to the Ran-binding protein 2 (RANBP2) in inflammatory myofibroblastic tumour. Genes Chromosomes Cancer 2003, 37:98-105.
40. Tort F., Pinyol M., Pulford K., Roncador G., Hernandez L., Nayach I., Kluin-Nelemans H.C., Kluin P., Touriol C., Delsol G., Mason D., Campo E. Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab. Invest. 2001, 81:419-426.
41. Trinei M., Lanfrancone L., Campo E., Pulford K., Mason D.Y., Pelicci P.G., Falini B. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res. 2000, 60:793-798.
42. Falini B., Pulford K., Pucciarini A., Carbone A., De Wolf-Peeters C., Cordell J., Fizzotti M., Santucci A., Pelicci P.G., Pileri S., Campo E., Ott G., Delsol G., Mason D.Y. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood 1999, 94:3509-3515.
43. Touriol C., Greenland C., Lamant L., Pulford K., Bernard F., Rousset T., Mason D.Y., Delsol G. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 2000, 95:3204-3207.
44. Drexler H.G., Gignac S.M., von Wasielewski R., Werner M., Dirks W.G. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 2000, 14:1533-1559.
45. Bitter M.A., Franklin W.A., Larson R.A., McKeithan T.W., Rubin C.M., Le Beau M.M., Stephens J.K., Vardiman J.W. Morphology in Ki-1(CD30)-positive non-Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5)(p23;q35). Am. J. Surg. Pathol. 1990, 14:305-316.
46. Shiota M., Mori S. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Leukemia 1997, 11(Suppl. 3):538-540.
47. Harris N.L., Jaffe E.S., Stein H., Banks P.M., Chan J.K., Cleary M.L., Delsol G., De Wolf-Peeters C., Falini B., Gatter K.C. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 1994, 84:1361-1392.
48. Falini B., Bigerna B., Fizzotti M., Pulford K., Pileri S.-A., Delsol G., Carbone A., Paulli M., Magrini U., Menestrina F., Giardini R., Pilotti S., Mezzelani A., Ugolini B., Billi M., Pucciarini A., Pacini R., Pelicci P.G., Flenghi L. ALK expression defines a distinct group of T/null lymphomas with a wide morphological spectrum. Am. J. Pathol. 1998, 153:875-886.
49. Grisendi S., Bernardi R., Rossi M., Cheng K., Khandker L., Manova K., Pandolfi P.P. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005, 437:147-153.
50. Lim M.J., Wang X.W. Nucleophosmin and human cancer. Cancer Detect. Prev. 2006, 30:481-490.
51. Armstrong F., Duplantier M.M., Trempat P., Hieblot C., Lamant L., Espinos E., Racaud-Sultan C., Allouche M., Campo E., Delsol G., Touriol C. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene 2004, 23:6071-6082.
52. Armstrong F., Lamant L., Hieblot C., Delsol G., Touriol C. TPM3-ALK expression induces changes in cytoskeleton organization and confers higher metastatic capacities than other ALK fusion protein. Eur. J. Cancer 2007, 43:640-646.
53. Chiarle R., Simmons W.J., Cai H., Dhall G., Zamo A., Raz R., Karras J.G., Levy D.E., Inghirami G. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat. Med. 2005, 11:623-629.
54. Marzec M., Kasprzycka M., Ptasznik A., Wlodarski P., Zhang Q., Odum N., Wasik M.A. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab. Invest. 2005, 85:1544-1554.
55. Zamo A., Chiarle R., Piva R., Howes J., Fan Y., Chilosi M., Levy D.E., Inghirami G. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002, 21:1038-1047.
56. Miething C., Grundler R., Fend F., Hoepfl J., Mugler C., von Schilling C., Morris S.W., Peschel C., Duyster J. The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model. Oncogene 2003, 22:4642-4647.
57. Kuefer M.U., Look A.T., Pulford K., Behm F.G., Pattengale P.K., Mason D.Y., Morris S.W. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 1997, 90:2901-2910.
58. Lange K., Uckert W., Blankenstein T., Nadrowitz R., Bittner C., Renault J.C., van Snick J., Feller A.C., Harmut M. Overexpression of NMP-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. Oncogene 2003, 22:517-527.
59. Turner S.D., Tooze R., Maclennan K., Alexander D.R. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene 2003, 22:7750-7761.
60. Chiarle R., Gong J.Z., Guasparri I., Pesci A., Cai J., Liu J., Simmons W.J., Dhall G., Howes J., Piva R., Inghirami G. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumours. Blood 2003, 101:1919-1927.
61. Jager R., Hahne J., Jacob A., Egert A., Schenkel J., Wernert N., Schorle H., Wellmann A. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas. Anticancer Res. 2005, 25:3191-3196.
62. Piva R., Chiarle R., Manazza A.D., Taulli R., Simmons W., Ambrogio C., D'Escamard V., Pellegrino E., Ponzetto C., Palestro G., Inghirami G. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood 2006, 107:689-697.
63. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S.-I., Watanabe H., Kurashina K., Hatanaka H., Bando M., Ohno S., Ishikawa Y., Aburatani H., Niki T., Sohara Y., Sugiyama Y., Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
64. Rikova K., Guo A., Zeng O., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L., Mitchell J., Wetzel R., MacNeill J., Ren J.M., Yuan J., Bakalarski C.E. Global survey of phosphotyrosine signalling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
65. Takeushi K., Choi Y.L., Togashi Y., Soda M., Hatano S., Inamura K., Takada S., Ueno T., Yamashita Y., Satoh Y., Okumura S., Nakagawa K., Ishikawa Y. Mano H. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin. Cancer Res. 2009, 15:3143-3149.
66. Choi Y.L., Takeuchi K., Soda M., Inamura K., Togashi Y., Hatano S., Enomoto M., Hamada T., Haruta H., Watanabe H., Kurashina K., Hatanaka H., Ueno T., Takada S., Yamashita Y., Sugiyama Y., Ishikawa Y., Mano H. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 2008, 68:4971-4976.
67. Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., Choi H.G., Kim J., Chiang D., Thomas R., Lee J., Richards W.G., Sugarbaker D.J., Ducko C., Lindeman N., Marcoux J.P., Engelman J.A., Gray N.S., Lee C., Meyerson M., Jänne P.A. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 2008, 14:4275-4283.
68. Soda M., Takada S., Takeuchi K., Choi Y.L., Enomoto M., Ueno T., Haruta H., Hamada T., Yamashita Y., Ishikawa Y., Sugiyama Y., Mano H. A mouse model for EML4-ALK-positive lung cancer. Proc. Natl. Acad. Sci. USA 2008, 105:19893-19897.
69. C. Garcia-Echeverria, T. Kanazawa, E. Kawahara, K. Masuya, N. Matsuura, T. Miyake, O. Ohmori, I. Umemura, R. Steensma, G. Chopiuk, J. Jiang, Y. Wan, Q. Ding, Q. Zhang, N.S. Gray, D. Karanewsky, Preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. NOVARTIS PHARMA, G.M.B.H.: WO2005016894 A1, 2005.
70. Perner S., Wagner P.L., Demichelis F., Mehra R., LaFargue C.J., Moss B.J., Arbogast S., Soltermann A., Weder W., Giordano T.J., Beer D.G., Rickman D.S., Chinnaiyan A.M., Moch H., Rubin M.A. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 2008, 10:298-302.
71. Solomon B., Varella-Garcia M., Camidge D.R. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J. Thorac. Oncol. 2009, 4:1450-1454.
72. Inamura K., Takeuchi K., Togashi Y., Nomura K., Ninomiya H., Okui M., Satoh Y., Okumura S., Nakagawa K., Soda M., Lim Choi Y., Niki T., Mano H., Ishikawa Y. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J. Thorac. Oncol. 2008, 3:13-17.
73. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., Solomon B., Stubbs H., Admane S., McDermott U., Settleman J., Kobayashi S., Mark E.J., Rodig S.J., Chirieac L.R., Kwak E.L., Lynch T.J., Iafrate A.J. Clinical features and outcome of patients with non-small-cell lung cancer who harbour EML4-ALK. J. Clin. Oncol. 2009, 27:4247-4253.
74. Martelli M.P., Sozzi G., Hernandez L., Pettirossi V., Navarro A., Conte D., Gasparini P., Perrone F., Modena P., Pastorino U., Carbone A., Fabbri A., Sidoni A., Nakamura S., Gambacorta M., Fernández P.L., Ramirez J., Chan J.K., Grigioni W.F., Campo E., Pileri S.A., Falini B. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am. J. Pathol. 2009, 174:661-670.
75. Sozzi G., Martelli M.P., Conte D., Modena P., Pettirossi V., Pileri S.A., Falini B. The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues. Haematologica 2009, 94:1307-1311.
76. Mano H., Takeuchi K. EML4-ALK fusion in lung. Am. J. Pathol. 2010, 176:1552-1553.
77. Horn L., Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J. Clin. Oncol. 2009, 27:4232-4235.
78. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to Gefitinib therapy. Science 2004, 304:1497-1500.
79. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Jänne P.A., Joshi V.A., McCollum D., Evans T.L., Muzikansky A., Kuhlmann G.L., Han M., Goldberg J.S., Settleman J., Iafrate A.J., Engelman J.A., Haber D.A., Johnson B.E., Lynch T.J. First-line Gefitinib in patients with advanced non-small-cell lung cancer harbouring somatic EGFR mutations. J. Clin. Oncol. 2008, 26:2442-2449.
80. Griffin C.A., Hawkins A.L., Dvorak C., Henkle C., Ellingham T., Perlman E.J. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumours. Cancer Res. 1999, 59:2776-2780.
81. Coffin C.M., Patel A., Perkins S., Elenitoba-Johnson K.S.J., Perlman E., Griffin C.A. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumour. Mod. Pathol. 2001, 14:569-576.
82. Bridge J.A., Kanamori M., Ma Z., Pickering D., Hill D.A., Lydiatt W., Lui M.Y., Colleoni G.W., Antonescu C.R., Ladanyi M., Morris S.W. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumour. Am. J. Pathol. 2001, 159:411-415.
83. Lawrence B., Perez-Atayde A., Hibbard M.K., Rubin B.P., Dal Cin P., Pinkus J.L., Pinkus G.S., Xiao S., Yi E.S., Fletcher C.D., Fletcher J.A. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumours. Am. J. Pathol. 2000, 157:377-384.
84. Panagopoulos I., Nilsson T., Domanski H.A., Isaksson M., Lindblom P., Mertens F., Mandahl N. Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumour. Int. J. Cancer 2006, 118:1181-1186.
85. Gascoyne R.D., Lamant L., Martin-Subero J.I., Lestou V.S., Harris N.L., Müller-Hermelink H.-K., Seymour J.F., Campbell L.J., Horsman D.E., Auvigne I., Espinos E., Siebert R., Delsol G. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of six cases. Blood 2003, 102:2568-2573.
86. De Paepe P., Baens M., van Krieken H., Verhasselt B., Stul M., Simons A., Poppe B., Laureys G., Brons P., Vandenberghe P., Speleman F., Praet M., De Wolf-Peeters C., Marynen P., Wlodarska I. ALK activation by the CTLC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 2003, 102:2638-2641.
87. Onciu M., Behm F.G., Downing J.R., Shurtleff S.A., Raimondi S.C., Ma Z., Morris S.W., Kennedy W., Jones S.C., Sandlund J.T. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of two cases. Blood 2003, 102:2642-2644.
88. Jazii F.R., Najafi Z., Malekzadeh R., Conrads T.P., Ziaee A.A., Abnet C., Yazdznbod M., Karkhane A.A., Salekdeh G.H. Identification of squamous cell carcinoma associated proteins by proteomics and loss of β tropomyosin expression in esophageal cancer. World J. Gastroenterol. 2006, 12:7104-7112.
89. Du X.-L., Hu H., Lin D.-C., Xia S.-H., Shen X.-M., Zhang Y., Luo M.-L., Feng Y.-B., Cai Y., Xu X., Han Y.-L., Zhan O.-M., Wanget M.-R. Proteomic profiling of proteins dysregulated in Chinese esophageal squamous cell carcinoma. J. Mol. Med. 2007, 85:863-875.
90. + histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. Blood 2008, 112:2965-2968.
91. Bai R.-Y., Ouyang T., Miething C., Morris S.W., Peschel C., Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signalling pathway. Blood 2000, 96:4319-4327.
92. Zou H.Y., Li Q., Lee J.H., Arango M.E., McDonnell S.R., Yamazaki S., Koudriakova T.B., Alton G., Cui J.J., Kung P.-P., Nambu M.D., Los G., Bender S.L., Mroczkowski B., Christensen J.G. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007, 67:4408-4417.
93. Mano H. Non-solid oncogenes in solid tumours: EML4-ALK fusion genes in lung cancer. Cancer Sci. 2008, 99:2349-2355.
94. LoRusso P.M., Eder J.P. Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology. Expert. Opin. Invest. Drugs 2008, 17:1013-1028.
95. Deininger M., Buchdunger E., Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105:2640-2653.
96. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., Deininger M.W.N., Silver R.T., Goldman J.M., Stone R.M., Cervantes F., Hochhaus A., Powell B.L., Gabrilove J.L., Rousselot P., Reiffers J., Cornelissen J.J., Hughes T., Agis H., Fischer T., Verhoef G., Shepherd J., Saglio G., Gratwohl A., Nielsen J.L., Radich J.P., Simonsson B., Taylor K., Baccarani M., So C., Letvak L., Larson R.A. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006, 355:2408-2417.
97. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009, 9:28-39.
98. Liu Y., Gray N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2006, 2:358-364.
99. Noble M.E.M., Endicott J.A., JOhnson L.N. Protein kinase inhibitors: insights into drug design from structure. Science 2004, 303:1800-1805.
100. Gunby R.H., Ahmed S., Sottocornola R., Gasser M., Redaelli S., Mologni L., Tartari C.J., Belloni V., Gambacorti-Passerini C., Scapozza L. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling. J. Med. Chem. 2006, 49:5759-5768.
101. Gunby R.H., Tartari C.J., Porchia F., Donella-Deana A., Scapozza L., Gambacorti-Passerini C. An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinase. Haematologica 2005, 90:988-990.
102. Coluccia A., Gunby R.H., Tartari C.J., Scapozza L., Gambacorti-Passerini C., Passoni L. Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy. Expert Opin. Ther. Targets 2005, 9:515-532.
103. Cheng M., Ott G.R. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma. Anti-Cancer Agents Med. Chem. 2010, 10:236-249.
104. Christensen J.G., Zou H.Y., Arango M.E., Li Q., Lee J.H., McDonnell S.R., Yamazaki S., Alton G.R., Mroczkowski B., Los G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 2007, 6:3314-3322.
105. McDermott U., Iafrate A.J., Gray N.S., Shioda T., Classon M., Maheswaran S., Zhou W., Choi H.G., Smith S.L., Dowell L., Ulkus L.E., Kuhlmann G., Greninger P., Christensen J.G., Haber D.A., Settleman J. Genomic alterations of anaplastic lymphoma kinase may sensitize tumours to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008, 68:3389-3395.
106. Galkin A.V., Melnick J.S., Kim S., Hood T.L., Li N., Li L., Xia G., Steensma R., Chopiuk G., Jiang J., Wan Y., Ding P., Liu Y., Sun F., Schultz P.G., Gray N.S., Warmuth M. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc. Natl. Acad. Sci. USA 2007, 104:270-275.
107. Sabbatini P., Korenchuk S., Rowand J.L., Groy A., Liu Q., Leperi D., Atkins C., Dumble M., Yang J., Anderson K., Kruger R.G., Gontarek R.R., Maksimchuk K.R., Suravajjala S., Lapierre R.R., Shotwell J.B., Wilson J.W., Chamberlain S.D., Rabindran S.K., Kumar R. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol. Cancer Ther. 2009, 8:2811-2820.
108. Chamberlain S.D., Redman A.M., Wilson J.W., Deanda F., Shotwell J.B., Gerding R., Lei H., Yang B., Stevens K.L., Hassell A.M., Shewchuk L.M., Leesnitzer M.A., Smith J.L., Sabbatini P., Atkins C., Groy A., Rowand J.L., Kumar R., Mook R.A., Moorthy G., Patnaik S. Optimization of 4, 6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity. Bioorg. Med. Chem. Lett. 2009, 19:360-364.
109. Wan W., Albom M.S., Quail M.R., Becknell N.C., Weinberg L.R., Reddy D.R., Holskin B.P., Angeles T.S., Underiner T.L., Meyer S.L., Hudkins R.L., Dorsey B.D., Ator M.A., Ruggeri B.A., Cheng M. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood 2006, 107:1617-1623.
110. Milkiewicz K.L., Weinberg L.R., Albom M.S., Angeles T.S., Cheng M., Ghose A.K., Roemmele R.C., Theroff J.P., Underiner T.L., Zificsak C.A., Dorsey B.D. Synthesis and structure-activity relationships of 1, 2, 3, 4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg. Med. Chem. 2010, 18:4351-4362.
111. G.R. Ott, M. Cheng, R. Tripathy, R. McHugh, L. Weinberg, K.L. Milkiewicz, A.V. Anzalone, T.J. Underiner, M.A. Curry, H.J. Breslin, M.R. Quail, L. Lu, W. Wan, T.S. Angeles, M.S. Albom, L. Aimone, M.A. Ator, M.A. Ruggeri, B.D. Dorsey. Discovery of a potent, selective, orally bioavailable inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity in animal models of anaplastic large-cell lymphoma, AACR Translational Cancer Medicine 2008: Bridging the Lab and the Clinic in Cancer Medicine, November, 2008.
112. M.R. Quail, L. Lu, M. Ghose, W. Wan, G.R. Ott, B.D. Dorsey, B.A. Ruggeri, M. Cheng, In vitro activity and in vivo efficacy of benzazepinone ALK inhibitor in EML4-ALK positive and negative non-small cell lung cancer-derived cell lines, 100th AACR Annual Meeting. Denver, CO, USA, 18-22 April 2009.
113. L. Lu, M.R. Quail, M. Jones, M. Ghose, A. DeVine, G.R. Ott, S. Jones-Bolin, B.D. Dorsey. In vitro activity and in vivo efficacy of a benzazepinone ALK inhibitor on human neuroblastoma-derived cell lines. 100th AACR Annual Meeting. Denver, CO, USA, 18-22 April 2009.
114. Li R., Xue L., Zhu T., Jiang Q., Cui X., Yan Z., McGee D., Wang J., Gantla V.R., Pickens J.C., McGrath D., Chucholowski A., Morris S.W., Webb T.R. Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase. J. Med. Chem. 2006, 49:1006-1015.
115. W.C. Shakespeare, V.M. Rivere, F. Wang, S. Liu, W.-S. Huang, R. Anjum, S. Zhang, J. Keats, S.D. Wardwell, Y. Ning, Y. Wang, D. Zou, M. Thomas, F. Li, J. Qi, J. Romero, L. Cai, T. Dwight, Y. Xu, R. Xu, R. Dodd, Q. Xu, V.R. Fantin, A. Kohlmann, L. Xue, J. Sparks, L. Commodore, T. Zhou, X. Lu, S. Zech, L.E. Moran, D. Roden, Q.K. Mohemmad, H. Jang, X. Zhu, N.I. Narasimhan, D. Dalgarno, T. Clackson, Discovery of potent and selective orally active inhibitor of anaplastic lymphoma kinase, 100th AACR Annual Meeting. Denver, CO, USA, 18-22 April 2009.
116. S. Zhang, F. Wang, J. Keats, Y. Ning, S.D. Wardwell, L. Moran, Q.K. Mohemmad, E. Ye, R. Anjum, Y. Wang, X. Zhu, J.J. Miret, D. Dalgarno, N.I. Narasimhan, T. Clackson, W.C. Shakespeare, V.M. Rivera, AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066. 101st AACR Annual Meeting. Washington, DC, USA, 17-21 April 2010.
117. V.M. Rivera, R. Anjum, F. Wang, S. Zhang, J. Keats, Y. Ning, S.D. Wardwell, L. Moran, E. Ye, D.-Y. Chun, Q.K. Mohemmad, S. Liu, W.-S. Huang, Y. Wang, M. Thomas, F. Li, J. Qi, J. Miret, J.D. Iuliucci, D. Dalgarno, N.I. Narasimhan, T. Clackson, W.C. Shakespeare, Efficacy and pharmacodynamic analysis of AP26133, a potent and selective orally active inhibitor of Anaplastic lymphoma kinase (ALK), 101st AACR Annual Meeting. Washington, DC, USA, 17-21 April 2010.
118. D.R. Camidge, J. Christensen, Y.J. Bang, A.T. Shaw, D.B. Costa, R. Salgia, B.J. Dezube, G.I. Shapiro, P.A. Janne, R.G. Maki, B. Solomon, E.L. Kwak, W. Tan, S.M. Shreeve, K. Wilner, J.W. Clark, J. Iafrate, in: Addressing Right Drug/Right Target/Right Patient in Phase I Studies to Accelerate Bench to Clinical Benefit Time: ALK Gene Rearrangements and Development of PF-02341066 in NSCLC, AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer. Coronado, CA, USA, 11-14 January 2010.
119. Y. Bang, A. Kwak, A.T. Shaw, D.R. Camidge, A.J. Iafrate, R.G. Maki, B.J. Solomon, S.I. Ou, R. Salgia, J.W. Clark, Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC), J. Clin. Oncol. 28(18) (2010) (Suppl. 3).
120. Sharma S.V., Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 2007, 21:3214-3231.
121. Jänne P.A., Gray N., Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discov. 2009, 8:709-723.
122. Carter T.A., Wodicka L.M., Shah N.P., Velasco A.M., Fabian M.A., Treiber D.K., Milanov Z.V., Atteridge C.E., Biggs W.H., Edeen P.T., Floyd M., Ford J.M., Grotzfeld R.M., Herrgard S., Insko D.E., Mehta S.A., Patel H.K., Pao W., Sawyers L.C., Varmus H., Zarrinkar P.P., Lockhart D.J. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. USA 2005, 102:11011-11016.
123. Bikker J.A., Brooijmans N., Wissner A., Mansour T.S. Kinase domain mutations in cancer: implications for small molecule drug design strategies. J. Med. Chem. 2009, 52:1493-1590.
124. Yun C.-H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.-K., Meyerson M., Eck M.J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. USA 2008, 105:2070-2075.
125. Jackman D., Pao W., Riely G.J., Engelman J.A., Kris M.G., Jänne P.A., Lynch T., Johnson B.E., Miller V.A. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non small cell lung cancer. J. Clin. Oncol. 2010, 28:357-360.
126. Lu L., Ghose A.K., Quail M.R., Albom M.S., Durkin J.T., Holskin B.P., Angeles T.S., Meyer S.L., Ruggeri B.A., Cheng M. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors. Biochemistry 2009, 48:3600-3609.